In the present study we showed that LcS administration twice
a day (65 ml respectively with a LcS concentration of 108/ml)
in patients with acute gastroenteritis has significant effects in
the reduction of bowel movements, positive effects on kidney
function and inflammation.We suggest that additional LcS administration
should be a valuable therapy in patients with acute
gastroenteritis who present with high inflammation markers
and/or acute impaired kidney function. Due to our limited study
design in our investigator initiated study and the variability
of the observed patients recruited from an emergency room
with a reach of 300,000 people, a double blinded, placebo controlled
study under standard conditions is needed to confirm
our findings.